YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Check out the companies making the biggest moves midday: Super Micro Computer — Shares surged 25% after the server maker reported preliminary fourth-quarter results that featured much stronger profitability than investors had expected, off…
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at n…
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Eliminatio…
Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s price grew 91.62% from a year ago, while it registered an 80.98% increase year-to-date. On April 16, Vir Biotechnolog…
Over the last 7 days, the United States market has dropped 29%, and in the past year, it is down 82%, though earnings are forecast to grow by 16% annually. Despite these challenging conditions, identifying stocks with solid financials can…
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Eliminat…
SAN FRANCISCO, April 09, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it stopped its Phase 3 Hunger Eliminat…
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of Billionaire Stan Druckenmiller’s 10 Small and Mid-Cap Stock Picks with Huge Upside Potential. Teva Pharmaceutical Industries Limited (NYSE:TEVA) first appeared in the 13F portfol…
Aardvark Therapeutics, Inc. (NASDAQ:AARD) is one of the penny stocks with potential to rise 1000 percent. Aardvark Therapeutics said on March 23, 2026, that it had voluntarily paused its Phase 3 HERO and open-label extension trials of ARD-…
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at…
LOS ANGELES, March 11, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aardvark Therapeutics, Inc., ("Aardvark" or the "Company") (NASDAQ:AARD) investors that the firm has initiated an investigation into possible securities fraud, an…
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at…
Health care stocks declined late Monday afternoon with the NYSE Health Care Index falling 1.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
(RTTNews) - Aardvark Therapeutics Inc. (AARD) announced that it has voluntarily paused the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO study is a randomized, double-blind, placebo-controlled Phase 3 trial evalu…
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways…
SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: TD Cowen upgraded Ametek (AME) to Buy from H…
Rhythm Pharmaceuticals said Thursday said it would send it would send its leading drug into registrational testing for Prader-Willi. Continue Reading
Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week. InvestingPro subscribers always get first dibs on market-moving AI analyst comments. Upgrade today! Carvana What happened? On Monday,…
[Historic buildings of the financial district in lower Manhattan, New York City near Wall Street] deberarr Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the…
Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) Ne…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: KeyBanc upgraded Datadog (DDOG) to Overweigh…
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathway…
Worawith Ounpeng/iStock via Getty Images LB Pharmaceuticals (LBRX [https://seekingalpha.com/symbol/LBRX]) climbed ~26% on Thursday as the New York-based biopharma, focused on developing drugs for neurological conditions such as schizophren…
Small-cap biotech stocks, while lacking the scale and financial stability of larger pharmaceutical giants, often have high growth potential. These companies are motivated by ground-breaking research, novel therapeutic approaches, and the p…
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways…
* Aardvark Therapeutics press release [https://seekingalpha.com/pr/20200202-aardvark-therapeutics-reports-second-quarter-2025-financial-results-and-provides-pipeline-and] (NASDAQ:AARD [https://seekingalpha.com/symbol/AARD]): Q2 GAAP EPS of…
Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients discontinuing GLP-1RA therapy, while Phase 2 ST…
SAN DIEGO - Aardvark Therapeutics, Inc. (NASDAQ:AARD), a $242 million market cap biotech company with a strong financial health score according to InvestingPro, announced Tuesday that its investigational drug ARD-201 demonstrated approxima…
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases…
BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their famil…
Investing.com - H.C. Wainwright initiated coverage on Aardvark Therapeutics Inc (NASDAQ:AARD) Monday with a Buy rating and a $40.00 price target. According to InvestingPro data, analyst targets for AARD range from $20 to $50, with the stoc…
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways…
Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General Counsel SAN…
Phase 3 HERO trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS); data readout expected in early 2026$151.3 million in cash, cash equivalents, and short-term investments supports projected operatio…